Drugmaker Biogen is pulling the plug on its controversial Alzheimer's drug Aduhelm, following disappointing sales. It had been expected to be a blockbuster product.Biogen says patients currently taking Aduhelm will have access to it until November 1, but patients taking the drug in clinical trials will lose access May 1.